Piramal acquires portfolio of drugs from Mallinckrodt LLC
Monday, March 20, 2017, 9:56 AM
Mumbai based, Piramal Enterprises Limited’s UK subsidiary, Critical Care has acquired a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC. The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. The acquisition was for a cash consideration of USD 171 million.